Monday, 24 Feb 2020

You are here

Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease

The NEJM reports a randomized placebo controlled trial of nintedanib, a tyrosine kinase inhibitor, in systemic sclerosis patients with interstitial lung disease (ILD) resulted in less pulmonary decline, but had no effect on other features of systemic sclerosis. 

Systemic sclerosis patients were enrolled if within 7 years of disase onset (non-Raynaud’s) and had high-resolution computed tomographic scan showing lung fibrosis affecting at least 10% of the lungs. Patients were randomized to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over 52 weeks. 

Among 576 patients, 52% had diffuse cutaneous systemic sclerosis, and 48.4% were on background mycophenolate.

The prime outcome was the adjusted annual rate of change in FVC change:

  • nintedanib group : −52.4 ml per year
  • placebo group: −93.3 ml per year (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P=0.04)

Other outcomes were not significant including the modified Rodnan skin score and the SGRQ at week 52.

Diarrhea, was much more common in those receiving nintedanib (75.7% vs 31.6%).

Nintedanib (Ofev) is currently FDA approved for use in idiopathic pulmonary fibrosis. It may have protective benefits in systemic sclerosis patients who develop ILD, but does not appear to otherwise benefit extrapulmonary disease progression in systemic sclerosis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.